The Sabin Vaccine Institute’s Influenzer Initiative Resource Library is an asset library comprising 43 video and audio elements, now hosted on the CIDRAP IVR website, and providing communications and education on collaborative vaccine distribution systems, investment in sustainable influenza vaccine development and its connection to health and economic security, the potential of mRNA vaccine technology, and the role of influenza vaccine R&D in pandemic prevention.
Milestone
6.1.b
Communications and advocacy
In progress
High priority
Develop targeted and creative communications and advocacy strategies and necessary communication tools that build on the FVIVA and provide information on economic costs, the risk of future influenza pandemics, and the need for investment in influenza vaccine R&D.
Progress Highlights
Goodfellow 2025 used a modelling framework to assess the future impact and cost-effectiveness of next-generation influenza vaccines (NGIVs) in 186 countries. The results showed that NGIVs have the potential to significantly improve global health if made widely available and in many countries would be cost-effective compared to current seasonal vaccines, based on higher efficacy and reduced need for annual re-vaccination.
Fisman 2024 summarized published cost-effectiveness analyses of cell-based influenza vaccines in children and adults less than 65 years of age, critically assessed the assumptions and approaches used in these analyses, and considered the role of cell-based influenza vaccines for children and adults.
Procter 2024 used a combined epidemiologic and economic model to estimate the health impact and cost-effectiveness of next-generation influenza vaccines (NGIVs) in Thailand. Results showed that adoption of NGIVs could substantially reduce the burden of influenza in Thailand and are likely to be cost-effective, but that there could also be large up-front costs.
Waterlow 2023 evaluated the cost-effectiveness of next-generation influenza vaccines in children under 5 years of age in a low-income country with year-round influenza seasonality (Kenya).
WHO’s FVIVA will include communication tools and advocacy strategies.
Langer 2024 conducted a systematic literature review on the humanistic burden of influenza in adults 65 and older, considering the impact of influenza on a patient’s health-related quality of life, daily activities, and caregiver health and/or quality of life, and economic findings, including direct and indirect costs associated with influenza.
Krauland 2023 modeled the impact of more effective influenza vaccines on the burden of seasonal influenza and found that highly effective vaccines could dramatically reduce influenza burden.
Langer 2023 characterized the global clinical burden of seasonal influenza among adults 65 years of age and older and concluded that influenza exerts a considerable burden on older adults and healthcare systems, with high incidence of hospitalization and mortality.
Maleki 2023 characterized the global burden of influenza in the 18 to 64 years population, based on a systematic review of influenza-associated clinical and economic outcomes in several global regions. They concluded that high levels of hospitalization and outpatient visits demonstrated a clinical influenza-associated burden on patients and healthcare systems, which is exacerbated by comorbidities.
Waterlow 2023 used mathematical modeling to assess the potential health, epidemiologic, and economic impact of next-generation influenza vaccines in England and Wales, providing evidence for the FVVA and an investment case for their development and rollout.